Emyria Launches Drug Development Program Based on RWE
Filed with ASX · · 4 pages · English
Highlights: ● Emyria launches drug development program focused on mental health following deep analysis of its Real-World Evidence (RWE) generated from over 3,000 patients ● Emyria RWE has identified a unique dose range of cannabidiol that significantly reduces anxiety and stress symptoms in a specific patient patient population treated across Emyria’s clinical service subsidiary, Emerald Clinics
Earlier from Emyria
- Emyria Partners with Thought Leaders in Psychedelic Therapy
- Emyria Enters Data Deal with ZLD to Support Autism Trial
- Webinar on Global Partnership with Sapphire Medical Clinics
- Emyria Signs Real-World Data Agreement with Zelira
- Preliminary Final Report and Full Year Statutory Accounts
Later from Emyria
- Emyria Sees Strong Interest in IBS Study
- Emyria to Benefit from Final TGA Ruling on CBD Medicines
- Emyria Pursuing Registration of EMD-003 in CY2021
- FDA Position on RWE to Guide Registration
- Emyria wins digital health monitoring grant with UWA
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria